Nabi Biopharmaceuticals (NABI) Tops Q3 EPS by 2c
More News related to NABI
- Unusual 11 Mid-Day Movers 11/16: SPEX, NLST, DRAM, XJT Higher; PARD, CRXX, CAEI, CHIO Lower
- Morning Movers 11/16: SPEX, NLST, XJT, NABI, KHD, IBKC, SPA Higher; PARD, CRXX, CAEI Lower
- Biotech Movers: SPEX, NABI, ALKS Up; PARD, CRXX Down
- Nabi Biopharmaceuticals to Hold Conference Call
- GLAXO (GSK) and Nabi BioPharma (NABI) Announce Option and Licensing Agreement for NicVAX
More News related to Earnings
- Playboy (PLA) Reaches Agreement with American Media to Outsource Publishing Functions; Sees Profitability by Year-End '11
- Pinnacle Gas (PINN) to Form Special Committee to Review Possible Proposals, Including Asset Divestitures, Equity Offerings
- Bunge (BG) To Acquire Brazilian Sugarcane Company Moema in an Estimated $1.35B Transaction
- Net 1 UEPS (UEPS) Acquires MediKredit Integrated in $10M Transaction
- Google (GOOG) Acquires San Mateo Startup Teracent
Nabi Biopharmaceuticals (NASDAQ: NABI) reports Q3 loss of $0.14, 2 cents better the analyst estimate of ($0.16).
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
